4//SEC Filing
MOORE JOHN R 4
Accession 0001562180-24-003830
CIK 0001710072other
Filed
May 2, 8:00 PM ET
Accepted
May 3, 6:31 PM ET
Size
9.4 KB
Accession
0001562180-24-003830
Insider Transaction Report
Form 4
MOORE JOHN R
General Counsel
Transactions
- Sale
Common Stock
2024-05-02$18.91/sh−1,956$36,988→ 3,252 total - Exercise/Conversion
Common Stock
2024-05-01+5,208→ 5,208 total - Exercise/Conversion
Restricted Stock Units
2024-05-01−5,208→ 5,209 totalExercise: $0.00Exp: 2032-05-01→ Common Stock (5,208 underlying)
Footnotes (3)
- [F1]Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
- [F2]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.68 to $19.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.
Documents
Issuer
Edgewise Therapeutics, Inc.
CIK 0001710072
Entity typeother
Related Parties
1- filerCIK 0001191702
Filing Metadata
- Form type
- 4
- Filed
- May 2, 8:00 PM ET
- Accepted
- May 3, 6:31 PM ET
- Size
- 9.4 KB